Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.420
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.410
-0.010 (-0.70%)
After-hours: Apr 28, 2026, 6:58 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 4.67, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 228.87% from the current stock price of 1.42.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +181.69% | Apr 7, 2026 |
| BTIG | BTIG | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +181.69% | Feb 25, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +181.69% | Feb 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +322.54% | Feb 6, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +252.11% | Dec 2, 2025 |
Financial Forecast
Revenue This Year
236.05M
from 236.20M
Decreased by -0.06%
Revenue Next Year
196.74M
from 236.05M
Decreased by -16.65%
EPS This Year
-0.09
from -0.02
EPS Next Year
-0.15
from -0.09
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 283.9M | 295.2M | ||||||
| Avg | 236.1M | 196.7M | ||||||
| Low | 148.3M | 116.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 20.2% | 25.0% | ||||||
| Avg | -0.1% | -16.7% | ||||||
| Low | -37.2% | -50.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.15 | -0.05 | ||||||
| Avg | -0.09 | -0.15 | ||||||
| Low | -0.29 | -0.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.